复方丹参滴丸联合缬沙坦对糖尿病肾病尿蛋白及血粘度的影响
贾爱华1 ，史晓艳2 ，李艳艳1，杨彩彩1，刘晋津1，刘新艳1
（1.榆林市第一医院内分泌科，陕西 榆林，719000；2.榆阳区人民医院检验科，陕西 榆林，719000）
浏览次数：144次 下载次数：278次
摘要：
目的 探讨复方丹参滴丸联合缬沙坦对糖尿病肾病的临床疗效。方法 选择100例糖尿病肾病（Ⅲ期）患者，随机分为对照组和观察组，各50例，对照组使用缬沙坦，观察组使用复方丹参滴丸联合缬沙坦。比较治疗前、后两组ACR 及血粘度变化。结果 治疗后，观察组和对照组的ACR 均明显降低，差异有统计学意义（P<0.05）。治疗后，观察组的全血粘度及血浆粘度均降低（P<0.05）；对照组治疗前、后的全血粘度及血浆粘度比较，差异无统计学意义（P>0.05）。治疗后，观察组全血粘度低于对照组 （P<0.05）。结论 缬沙坦联合复方丹参滴丸治疗糖尿病肾病与单用缬沙坦相比，在降低尿蛋白同时还可明显降低全血粘度。
关键词：糖尿病肾病；复方丹参滴丸；缬沙坦
中图分类号：R587.2；R692.9 文献标志码：A文章编号：2096-1413(2017)31-0022-02
Clinical effect observation of compound Danshen dripping pills combined with valsartan on uring ACR and blood viscosity
in patients with diabetic nephropathy
JIA Ai-hua 1, SHI Xiao-yan 2, LI Yan-yan 1, YANG Cai-cai 1, LIU Jin-jin 1, LIU Xin-yan 1
(1. Department of Endocrinology, the First Hospital of Yulin, Yulin 719000；2. Clinical Laboratory, People``s Hospital of
Yuyang District, Yulin 719000, China)
ABSTRACT: Objective To observe the effects of compound Danshen dripping pills (DSP) combined with valsartan on diabetic nephropathy. Methods One hunderd diabetic nephropathy (Ⅲstage) patients were randomly divided into observation group and control group, with 50 cases in each group. The control group was treated with valsartan, the observation group was treated with compound DSP combined with valsartan. The urine trace albumin urocreatinine (ACR), blood viscosity and plasma viscosity were compared before and after treatment in the two group. Results After treatment, the ACR of the two groups were lower than before treatment （P<0.05）. The blood viscosity and plasma viscosity in the observation group obviously reduced, which were superior to the control group (P<0.05). Conclusion Compound DSP combined with valsartan can further effectively reduce urinary ACR, blood viscosity and plasma viscosity.
KEYWORDS: diabetic nephropathy; compound Danshen dripping pills; valsartan
参考文献：
[1] 中华医学会糖尿病分会.中国2 型糖尿病防治指南[J].中华糖尿病杂志,2014,6(7):447-498.
[2] 高震,张迎春.替米沙坦联合羟苯磺酸钙治疗老年糖尿病肾病合并高血压的临床效果[J].中国医药导报,2015,12(24):136-145.
[3] MOOYAART AL,VALK EJJ,VANES LA,et al.Genetic association in diabetic nephropathy: a meta-analysis[J].Diabetologia,2014,57(3):544-553.
[4] KAMIYAMA M,URUSHIHARA M,MORIKAWA T,et al.Oxidative stress/angiotensinogen/renin-angiotensin system axis in patients with diabetic nephropathy[J].Int J Mol Sci,2013,14(11):23045-23062
[5] LAMBERS HJ,WELDEGIORGIS M,LNKER LA,et al.Estimated GFR decline as a surrogate end point for kidney failure:a post hoc analysis from the reduction of end points in non -lnsulin -dependent diabetes with the angiotensin Ⅱantagonist losartan(RENAAL) study and lrbesartan diabetic nephropathy trial (IDNT) [J].Am J Kidney Dis,2014,63 (2): 244-250.
[6] 熊佳.复方丹参滴丸联合阿司匹林治疗冠心病的临床效果及其对血脂的影响[J].当代医学,2016,22(28):143-144.
[7] PUGSLEY MK.The angiotensin-Ⅱ( ATⅡ) receptor blocker olmesartan reduces renal damage in animal models of hypertension and diabetes [J].Proc West Pharmacol Soc,2005,48(1):35-38.
[8] 路万虹,张晓田,成少利.复方丹参滴丸对大鼠糖尿病肾病早期的肾脏保护及作用机制[J].西安交通大学学报:医学版,2016,37(1):128-133.
[9] LUO D,QIN Y,YUAN W,et al.Compound Danshen dripping pill for treating early diabetic retinopathy: a randomized, double -dummy, double-blind study[J].Evid Based Complement Alternat Med,2015 (1): 539185.
[10] 马世堂,戴国梁,程小桂,等.复方丹参滴丸与氯吡格雷抗血小板聚集协同作用[J].中药材,2014,37(10):1820-1825.
[11] YANG R,CHANG L,GUO BY,et al.Compound Danshen dripping pill pretreatment to prevent contrast -induced nephropathy in patients with acute coronary syndrome undergoing percutaneous coronary intervention[J].Evid Based Complement Alternat Med,2014,10(16):256-268.